Skip to main content

Topical Compounded Agents

Topical compounded creams combining amitriptyline, baclofen, gabapentin, ketamine, and lidocaine — alone or in multi-agent formulations — are widely prescribed for vulvodynia / provoked vestibulodynia, chronic pelvic pain, genital / perineal / rectal pain, and as adjuncts for Peyronie's-related discomfort, despite a thin evidence base dominated by retrospective series, case reports, and a single large placebo-controlled RCT that was negative for general chronic pain.[1][2] None of these formulations are FDA-approved. The rationale for continued use in urogenital practice rests on the argument that the vulvar vestibule and perineum have thin, richly innervated epithelium that allows topical agents to reach peripheral nociceptors at local tissue concentrations that skin overlying a joint or the back cannot.[3][4]

For the related comparator classes, see Gabapentinoids, Tricyclic antidepressants, SNRIs, NSAIDs and analgesics, and Local anesthetics.

Why topical in the urogenital tract​

The rationale for multi-agent topical therapy is multimodal peripheral analgesia — blocking several nociceptor mechanisms simultaneously while avoiding systemic exposure:[4][5]

TargetAgentPeripheral effect
Voltage-gated Na⁺ channelsLidocaine, amitriptyline (local-anesthetic-like)Blocks action-potential generation at the nociceptor terminal
NMDA receptors on primary afferentsKetamineReduces peripheral sensitization and wind-up
α2δ subunit of voltage-gated Ca²⁺ channelsGabapentinReduces excitatory neurotransmitter release
Peripheral GABA-B receptorsBaclofenModulates nociceptor–immune-cell cross talk
Mast-cell stabilization / H1AmitriptylineDampens neurogenic inflammation in vestibular epithelium

Topical formulations do not require transdermal delivery to the bloodstream — they act on peripheral targets in the tissue where they are applied, which is the pharmacologic argument for why genital mucosa may respond even when the same drugs fail through intact skin.[4]

The critical negative trial — Brutcher 2019​

Any discussion of compounded pain creams must be framed against the largest and most rigorous RCT performed to date.[1]

  • Design: three parallel placebo-controlled RCTs at a military treatment facility; n = 399 patients with localized chronic pain classified as neuropathic, nociceptive, or mixed
  • Formulations tested:
    • Neuropathic cream: ketamine + gabapentin + clonidine + lidocaine
    • Nociceptive cream: ketoprofen + baclofen + cyclobenzaprine + lidocaine
    • Mixed cream: ketamine + gabapentin + diclofenac + baclofen + cyclobenzaprine + lidocaine
  • Result: no difference vs placebo at 1 month for neuropathic pain (−0.1), nociceptive pain (−0.3), or mixed pain (−0.3)
  • Conclusion: "Compounded pain creams were not better than placebo creams, and their higher costs compared with approved compounds should curtail routine use"

A Lancet review echoed that centrally acting ingredients (ketamine, gabapentinoids) in compounded pain creams dilute peripherally acting agents that might otherwise be effective.[2]

Why the Brutcher trial does not close the book for urogenital use: the trial studied low-back, knee, and other cutaneous-distribution pain. It did not enroll patients with vulvodynia, vestibulodynia, genital or perineal pain. The vestibular epithelium is thin, non-keratinized, and densely innervated by C-fiber nociceptors — a fundamentally different pharmacokinetic and pharmacodynamic environment than skin over a joint.[3][4] This limitation is the scientific basis for continued use of topical agents in the urogenital population pending better trials.

Individual agents — evidence for urogenital use​

Topical lidocaine — strongest evidence​

Lidocaine blocks voltage-gated sodium channels on peripheral nociceptors. It is the only topical agent in this class with RCT-level evidence for urogenital pain.[5][6]

  • Zolnoun 2003 (prospective trial, n = 61): overnight 5% lidocaine ointment applied to the vestibule for a mean of 7 weeks — 76% of women reported ability to have intercourse (vs 36% before treatment; p = 0.002); intercourse-related pain fell by 39 points on a 100-mm VAS[6]
  • ACOG breast-cancer-survivor consensus 2021 — 4% aqueous lidocaine applied to the introitus for 3 min before intercourse reduced dyspareunia by 88% vs 38% placebo (double-blind RCT, n = 46)[7]
  • Vulvodynia State-of-the-Science review 2023 — overnight 5% lidocaine ointment and oral desipramine with 5% lidocaine cream carry the highest level of evidence (RCT / comparative-effectiveness) among all vulvodynia treatments[8]
  • Vestibulodynia UPDATe trial (NCT03844412) — multicenter RCT now enrolling, comparing 5% lidocaine + 0.02% oestradiol compound cream vs oral nortriptyline vs combined vs placebo; the first large RCT of a topical compound cream specifically for vestibulodynia[9]
  • Intravesical alkalinized lidocaine — AUA-recommended (Grade B) for IC/BPS; up to 12 h of pain and urgency relief.[10][11] Covered separately in Local anesthetics and IC/PBS

Typical compounding: 2–5% in ointment (preferred for vestibular tolerance) or aqueous base.

Topical gabapentin​

Gabapentin binds the α2δ subunit of voltage-gated calcium channels on peripheral sensory terminals.[5]

  • Boardman 2008 (retrospective, n = 51) — topical gabapentin 2–6% to the vulva for ≥8 weeks: mean pain score 7.26 → 2.49 (Δ −4.77; p < 0.001); 80% of patients achieved ≥50% pain improvement[12]
  • Ergisi 2023 narrative synthesis — 4 studies of topical gabapentin for vulvodynia all reported improvement, but all were uncontrolled; the review explicitly called for double-blind RCTs[13]
  • American Academy of Pain Medicine 2025 — "limited evidence from single observational studies suggests that gabapentin 6% might be effective for vulvodynia, burning pain, and itching"[3]

Do not conflate topical with oral. Brown 2018 (RCT, n = 89) showed oral extended-release gabapentin (1,200–3,000 mg/day) was not superior to placebo on tampon-test pain (adjusted mean 4.0 vs 4.3; p = 0.07) — a negative result that does not settle the topical question because tissue concentrations and off-target effects differ by route.[14]

Typical compounding: 2–6% in a cream or gel base.

Topical amitriptyline​

Acts through peripheral sodium-channel blockade, antihistaminic effects on mast cells (relevant to the neuroinflammatory model of vestibulodynia), and local serotonergic / noradrenergic receptor modulation. Systemic absorption at topical concentrations is minimal.[5][15]

  • ACOG Committee Opinion on persistent vulvar pain (2018) lists topical TCAs compounded into cream among commonly prescribed medications for vulvodynia[15]
  • Ruoss 2021 (single-clinic audit, n = 376 respondents) — amitriptyline 0.5% + oestriol 0.03% in an organogel applied to the vestibule: rated effective by 51–67% across age groups; stinging at application was the main adverse effect[16]
  • Vulvodynia State-of-the-Science review 2023 — amitriptyline cream and amitriptyline-with-baclofen cream showed pre-to-post pain reduction in non-RCT studies; no RCTs exist[8]

Typical compounding: 2–5% in a cream or organogel base.

Topical baclofen​

GABA-B agonist acting on peripheral receptors expressed on sensory terminals and resident immunocompetent cells in the vestibular epithelium. The mechanistic argument is explicitly one of modulating nociceptor–immune-cell–epithelial cell cross talk, not a requirement for transdermal delivery.[4]

  • Keppel Hesselink 2014 — case report of a 33-year-old woman with intractable vulvar and anal pain unresponsive to standard therapy; topical baclofen 5% + palmitoylethanolamide produced >50% symptom reduction at 3 months with return of pain-free intercourse[17]
  • AAFP dyspareunia review 2021 — "compounded muscle relaxants" listed among vulvodynia options (Level C)[18]

Typical compounding: 2–5% in a cream base.

Topical ketamine​

NMDA-receptor antagonist with additional peripheral sodium-channel and opioid-receptor activity at the high local concentrations achievable topically.[19][20]

  • Poterucha 2012 (Mayo Clinic, retrospective, n = 13) — topical amitriptyline-ketamine cream for genital, rectal, or perineal pain: 1 (8%) complete relief, 6 (46%) substantial, 4 (31%) some, 2 (15%) none — 85% overall response rate; only 1 patient reported occasional irritation; no systemic adverse effects. Diagnoses included vulvodynia, proctalgia fugax, coccydynia, pudendal neuralgia, and post-surgical perineal pain[21]
  • Cochrane 2025 — topical ketamine alone showed no clear evidence of benefit over placebo for chronic pain (low-certainty evidence); combination formulations were insufficiently studied[22]
  • AAPM 2025 — "small studies of topical ketamine alone did not find statistically significant benefit … smaller non-placebo-controlled trials of ketamine combined with amitriptyline and lidocaine found benefit for peripheral neuropathic pain"[3]
  • Sawynok 2014 — retrospective analyses of topical ketamine combinations show 40–75% response rates; controlled trials show benefit in only some outcomes; optimal dosing unclear[19]

Typical compounding: 2–10% in a cream or gel base. Plasma ketamine and norketamine are mostly below detection threshold even at high topical concentrations.[20]

Common compounded formulations​

FormulationTypical concentrationsPrimary urologic indicationBest evidenceReference
Lidocaine ointment (single-agent)5%Vulvodynia / vestibulodynia, dyspareuniaProspective + RCT[6][7][8]
Lidocaine + oestradiolLidocaine 5% + E₂ 0.02%Vestibulodynia (UPDATe)Ongoing multicenter RCT[9]
Gabapentin (single-agent)2–6%Vulvodynia, vestibular burningRetrospective n = 51, 80% ≥50% improvement[12]
Amitriptyline + ketamineAmitriptyline 2–5% + ketamine 2–5%Genital, rectal, perineal painRetrospective n = 13, 85% response[21]
Amitriptyline + oestriolAmitriptyline 0.5% + E₃ 0.03%Vulvodynia, pudendal neuralgiaClinic audit n = 376[16]
Amitriptyline + baclofenAmitriptyline 2% + baclofen 2–5%Vulvodynia / vestibulodyniaPre-post observational[8]
Baclofen + PEABaclofen 5% + PEA 1%Vulvodynia, proctodyniaCase reports[17]
Multi-agent (ABGKL)Amitriptyline 5% + baclofen 2% + gabapentin 5% + ketamine 5% + lidocaine 5%Chronic pelvic / genital painExpert opinion; no RCT for this combination[3]

Urologic applications​

Vulvodynia and provoked vestibulodynia — the primary indication​

  • ACOG 2018 lists topical local anesthetics, estrogen cream, and compounded TCAs as commonly prescribed first-line[15]
  • AAFP 2021 / 2025 lists compounded gabapentin, compounded muscle relaxants, and amitriptyline among pharmacologic options (Level C)[18][23]
  • Vulvodynia Therapeutic Research Summit 2024 identified neuroinflammation-directed agents — ketotifen fumarate, resiniferatoxin, specialized pro-resolving mediators, luteolin, alpha-lipoic acid — as the highest-priority targets for future research. The traditional compounded agents (amitriptyline, baclofen, gabapentin, ketamine) were not among the top-ranked agents, signaling that the field expects to move beyond empiric multi-agent creams.[24]

Genital, rectal, and perineal pain​

The Mayo Clinic amitriptyline-ketamine series[21] is the most direct evidence — 85% response rate across vulvodynia, proctalgia fugax, coccydynia, pudendal neuralgia, and post-surgical perineal pain. Small and uncontrolled, but the signal is consistent with the peripheral-target rationale and with the safety profile of topical delivery.

Chronic pelvic pain (CPP, CP/CPPS)​

No dedicated trials evaluate multi-agent compounded creams for CP/CPPS or female CPP as distinct from vulvodynia. The ACOG CPP Practice Bulletin (2020) recommends trigger-point injections for myofascial CPP (Level B); topical creams are used anecdotally as adjuncts to pelvic-floor physical therapy.[25][26]

Peyronie's disease​

Topical agents for PD are a distinct literature. The AUA PD guideline lists topical verapamil and liposomal rhSOD among investigational topical options.[27] A systematic review concluded that topical medications did not demonstrate consistent improvement across outcomes.[28] The H-100 gel (nicardipine + SOD + emu oil) showed a signal in a small acute-phase pilot RCT.[29] Multi-agent analgesic creams of the type discussed here are not first-line for PD and have no randomized evidence.

Practical prescribing​

Vehicle matters. Ointments are generally better tolerated than creams on vestibular tissue — creams contain preservatives and stabilizers that often produce burning on application; organogel bases improve drug penetration and tolerability.[15][16]

Application.

  • Thin layer to affected area (vestibule, perineum, penile shaft) 2–3 times daily
  • For vulvodynia / dyspareunia: may apply 15–30 min before intercourse for acute relief or on a scheduled basis for chronic management
  • Overnight lidocaine: 5% ointment to the vestibule at bedtime with a cotton ball held in place by underwear (the Zolnoun regimen)[6]

Adverse effects.

  • Local — stinging, burning, irritation at application site (most common; often vehicle-related)
  • Systemic — minimal at topical concentrations; ketamine and norketamine plasma levels are typically below detection threshold[20]
  • ACOG caution — "consider stopping all topical medications before prescribing a new course of therapy, as they may be contributing to burning pain symptoms"[15]

Cost and access.

  • None are FDA-approved; compounding pharmacies are regulated under section 503A or 503B of the FDCA
  • A typical 30-g supply of a multi-agent cream runs $55–$150 and is generally not covered by insurance[3]
  • Quality and concentration consistency vary between pharmacies — use vetted compounders

Clinical Positioning​

  • The largest compounded-cream RCT (Brutcher 2019, n = 399) was negative for neuropathic, nociceptive, and mixed chronic pain — but it did not study urogenital mucosa, which is the one anatomic environment where peripheral-target arguments are most defensible[1][2]
  • Start single-agent where possible. Overnight 5% lidocaine ointment and topical gabapentin 6% have the best supporting data in vulvodynia; escalate to multi-agent formulations only when single agents fail[6][12]
  • Lidocaine is the only agent with RCT support in this anatomic context; everything else in the class rests on retrospective series, case reports, or expert opinion[8]
  • Amitriptyline-ketamine cream is reasonable for genital, rectal, or perineal neuropathic pain after oral TCAs and gabapentinoids have failed or been poorly tolerated — 85% response in the Mayo series with minimal systemic exposure[21]
  • Oral negative trials do not indict the topical route. Oral gabapentin failed for vulvodynia in Brown 2018, but topical retrospective data remain encouraging because tissue concentrations differ by route[12][14]
  • Ointment > cream on vestibular tissue; burning on application is the most common reason patients abandon therapy and is often vehicle-related[15]
  • Discuss cost upfront. $55–$150 per tube with no insurance coverage is a meaningful barrier; set expectations before prescribing[3]
  • The field is moving past empiric multi-agent compounds. The Vestibulodynia UPDATe trial will be the first RCT of a topical compound for vestibulodynia, and the Vulvodynia Therapeutic Research Summit identified neuroinflammation-directed agents (ketotifen, resiniferatoxin, SPMs) as the next generation of targeted topicals[9][24]

See Also​

References​

1. Brutcher RE, Kurihara C, Bicket MC, et al. "Compounded topical pain creams to treat localized chronic pain: a randomized controlled trial." Ann Intern Med. 2019;170(5):309–318. doi:10.7326/M18-2736

2. Cohen SP, Vase L, Hooten WM. "Chronic pain: an update on burden, best practices, and new advances." Lancet. 2021;397(10289):2082–2097. doi:10.1016/S0140-6736(21)00393-7

3. Lawson E, Singla P, Adler J, et al. "Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician." Pain Med. 2025;pnaf130. doi:10.1093/pm/pnaf130

4. Keppel Hesselink JM, Kopsky DJ, Sajben N. "New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells." J Pain Res. 2016;9:757–762. doi:10.2147/JPR.S115407

5. Kocot-Kępska M, Zajączkowska R, Mika J, et al. "Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain — narrative review." Pharmaceutics. 2021;13(4):450. doi:10.3390/pharmaceutics13040450

6. Zolnoun DA, Hartmann KE, Steege JF. "Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis." Obstet Gynecol. 2003;102(1):84–87. doi:10.1016/s0029-7844(03)00368-5

7. American College of Obstetricians and Gynecologists. "Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

8. Schlaeger JM, Glayzer JE, Villegas-Downs M, et al. "Evaluation and treatment of vulvodynia: state of the science." J Midwifery Womens Health. 2023;68(1):9–34. doi:10.1111/jmwh.13456

9. Carey ET, Geller EJ, Rapkin A, et al. "Rationale and design of a multicenter randomized clinical trial of vestibulodynia: understanding pathophysiology and determining appropriate treatments (Vestibulodynia: UPDATe)." Ann Med. 2022;54(1):2885–2897. doi:10.1080/07853890.2022.2132531

10. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

11. Parsons CL, Zupkas P, Proctor J, et al. "Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis." J Sex Med. 2012;9(1):207–212. doi:10.1111/j.1743-6109.2011.02542.x

12. Boardman LA, Cooper AS, Blais LR, Raker CA. "Topical gabapentin in the treatment of localized and generalized vulvodynia." Obstet Gynecol. 2008;112(3):579–585. doi:10.1097/AOG.0b013e3181827c77

13. Ergisi M, Law A, Chaudhari N, et al. "Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis." Front Pain Res. 2023;4:1159268. doi:10.3389/fpain.2023.1159268

14. Brown CS, Bachmann GA, Wan J, Foster DC. "Gabapentin for the treatment of vulvodynia: a randomized controlled trial." Obstet Gynecol. 2018;131(6):1000–1007. doi:10.1097/AOG.0000000000002617

15. American College of Obstetricians and Gynecologists. Persistent Vulvar Pain — Committee Opinion No. 673 (reaffirmed). Washington, DC: ACOG; 2018.

16. Ruoss CM, Howard EA, Chan K, Stevenson PG, Vancaillie T. "Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: a single clinic audit of amitriptyline and oestriol in organogel." Aust N Z J Obstet Gynaecol. 2021;61(2):270–274. doi:10.1111/ajo.13292

17. Keppel Hesselink JM, Kopsky DJ, Sajben NL. "Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide." Arch Gynecol Obstet. 2014;290(2):389–393. doi:10.1007/s00404-014-3218-4

18. Hill DA, Taylor CA. "Dyspareunia in women." Am Fam Physician. 2021;103(10):597–604.

19. Sawynok J. "Topical and peripheral ketamine as an analgesic." Anesth Analg. 2014;119(1):170–178. doi:10.1213/ANE.0000000000000246

20. Kopsky DJ, Keppel Hesselink JM, Bhaskar A, et al. "Analgesic effects of topical ketamine." Minerva Anestesiol. 2015;81(4):440–449.

21. Poterucha TJ, Murphy SL, Rho RH, et al. "Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort." Pain Physician. 2012;15(6):485–488.

22. Ferraro MC, Cashin AG, Visser EJ, et al. "Ketamine and other NMDA receptor antagonists for chronic pain." Cochrane Database Syst Rev. 2025;8:CD015373. doi:10.1002/14651858.CD015373.pub2

23. Dalrymple SN, Hoeg L, Thacker H. "Female sexual dysfunction: common questions and answers." Am Fam Physician. 2025;111(5):433–442.

24. Krapf JM, Yong PJ, Berke MD, et al. "Executive summary of the Vulvodynia Therapeutic Research Summit." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006118

25. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

26. Namazi G, Chauhan N, Handler S. "Myofascial pelvic pain: the forgotten player in chronic pelvic pain." Curr Opin Obstet Gynecol. 2024;36(4):273–281. doi:10.1097/GCO.0000000000000966

27. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's disease: AUA guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

28. Hayat S, Brunckhorst O, Alnajjar HM, et al. "A systematic review of non-surgical management in Peyronie's disease." Int J Impot Res. 2023;35(6):523–532. doi:10.1038/s41443-022-00633-w

29. Twidwell J, Levine L. "Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study." Int J Impot Res. 2016;28(2):41–45. doi:10.1038/ijir.2015.22